YM443 in Subjects With Functional Dyspepsia

Phase 2

Completed

• Conditions: Nausea; Indigestion

• Registration Number: NCT00102310
• Lead Sponsor: Astellas Pharma Inc

Brief Summary

The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03-10
• Study First Submitted: 2005-01-26
• Study First Submitted QC: 2005-01-26
• Study First Posted: 2005-01-27
• Primary Completion: 2006-03-11
• Study Completion: 2006-03-11
• Status Verified: 2015-06
• Last Update Submitted: 2018-01-08
• Last Update Posted: 2018-01-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 416

Inclusion Criteria

• Ability to read and write in English.
• Written informed consent has been obtained.
• 18-75 years of age on the day the Informed Consent Form is signed.
• Men or women.
• Females, not pregnant, lactating or likely to become pregnant.
• Abdominal ultrasound and/or upper endoscopy findings that are judged as not clinically significant by the Investigator during Screening or within 4 weeks prior to Screening.
• Symptoms of FD at Visits 1 and 4 as defined by Rome II criteria.
• Subjects with a positive H. pylori breath test at Screening may be included in the study.
• Subjects with pH-metry results at Screening indicative of reflux may be included in the study.
• ECG, vital signs, and laboratory results that are judged as not clinically significant by the Investigator during Screening.

Exclusion Criteria

• Significant renal, hepatic, bilirubin, cardiovascular, pulmonary, endocrine, metabolic, hematological, neurologic, or gastrointestinal (other than the one being studied) condition.
• Subjects with diabetes mellitus are to be excluded.
• Congenital or acquired long QT syndrome, or uncontrolled arrhythmias.
• Prior surgery on the luminal GI tract.
• History of any major psychiatric disorder, current depression or anxiety, alcohol abuse, or substance abuse in the last 2 years.
• Any evidence or treatment for malignancy (with the exception of basal cell carcinoma) within the last 5 years.
• Confirmed structural gastrointestinal disease.
• Predominant symptoms of irritable bowel syndrome (IBS) (Rome II criteria) or gastroesophageal reflux disease (GERD) assessed at Visit 1 or 4.
• Female subjects who are pregnant, lactating, or are likely to become pregnant during the study.
• Males and females of child-bearing potential must be abstinent or agree to use contraceptive regimens throughout the study.
• Any history or condition which, in the opinion of the Investigator, makes the subject unsuitable for any of the procedures used during this study or would not allow for safe completion of the study.
• Known hypersensitivity to gastroprokinetics or proton pump inhibitors.
• Use of anti-ulcer medications, antacid/acid suppression medications, gastroprokinetics, aspirin (>325 mg daily), other NSAIDs, antibiotics, and other medications that effect the GI system within 2 weeks prior to Screening. Must be able to stay off these medications during the study, except for proton pump inhibitors (PPIs) administered during the PPI Run-in Period.
• Required use of concomitant medications known to adversely interact with other gastroprokinetic agents or proton pump inhibitors.
• H. pylori eradication therapy (PPIs, antibiotics, bismuth preparations) in the 2 weeks prior to the upper endoscopy.
• Treatment for H. pylori required during the study.
• Subject has received an investigational drug within 30 days or 10 half-lives, which ever is longer, or participated in more than 3 clinical studies within 12 months, prior to Visit 1.
• Previous treatment with YM443.
• Employees of the Yamanouchi Group or CROs involved in the study.
• More than one subject per household to participate in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (59)

Dr. Suresh Karne; 🇺🇸 Huntsville, Alabama, United States

James Thrasher, MD; 🇺🇸 Little Rock, Arkansas, United States

Dr. Dennis Riff; 🇺🇸 Anaheim, California, United States

Dr. Peter Winkle; 🇺🇸 Cypress, California, United States

Dr. Ramin Farsad; 🇺🇸 Encinitas, California, United States

Dr. Prahalad Jajodia; 🇺🇸 Fresno, California, United States

Dr. Gurmej Dhillon; 🇺🇸 Fresno, California, United States

Dr. Steven Duckor; 🇺🇸 Orange, California, United States

Dr. Theodor Feinstat; 🇺🇸 Roseville, California, United States

Scott Levenson, MD; 🇺🇸 San Carlos, California, United States

Scroll for more (49 remaining)